Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-10
2006-01-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S378000
Reexamination Certificate
active
06984650
ABSTRACT:
The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.
REFERENCES:
patent: 0245825 (1987-11-01), None
patent: WO 91/15479 (1991-10-01), None
patent: WO 96/21742 (1996-07-01), None
patent: WO 97/04774 (1997-02-01), None
patent: WO 99/18124 (1999-04-01), None
patent: WO 99/50664 (1999-10-01), None
patent: WO 00/25134 (2000-05-01), None
patent: WO 00/39070 (2000-07-01), None
patent: WO 00/57915 (2000-10-01), None
Comment of Saul J. Karpen, M.D., Ph.D. on Parks et al.,Hepatology30:4 1107-1109 (Oct. 1999).
Knowles et al., “Action of 5-isoxazolones on enamines,”J. Chem. Soc, Perk. Trans. 19-10:1240-1243 (1972). (abstract only).
Krey et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,”Molecular Endocrinology11(6):779-791 (Jun. 1997).
Makishima et al., “Identification of a nuclear receptor for bile acids,”Science284:1362-1365 (1999).
Maloney et al., “Identification of a chemical tool for the orphan nuclear receptor FXR,”Journal of Medicinal Chemistry43(16):2971-2974 (Aug. 2000).
Nichols et al., “Development of a scintillation proximity assay for peroxisome proliferator-activated receptor γ ligand binding domain,”Analytical Biochemistry257(2):112-119 (Mar. 1998).
Nolte et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ,”Nature395:137-143 (Sep. 1998).
Parks et al., Bile acids: natural ligands for an orphan nuclear receptor,:Science284:1365-1368 (1999).
Yao et al., “The nuclear hormone receptor coactivator SRC-1 is a specific target of p300,”Proc. Natl. Acad. Sci. USA93:10626-10631 (1996).
Zhou et al., “Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer,”Molecular Endocrinology12(10):1594-1604 (Oct. 1998).
Goldstein et al.,Regulation of the mevalonate pathway,Nature 343:425-430 (Feb. 1, 1990).
Fujita e al.,Moleculare cloning, expression, and characterization of human intestinal 15-kDa protein,European J. Biochemistry 233:406-413 (1995).
Kanda et al.,Regulation of expression of human intestinal bild acid-binding protein in Caco-2 cells,Biochem Journal 330:261-265 (1998).
Forman et al.,Identification of a Nuclear Receptor that is Activated by Farnesol Metabolites,Cell 81:687-693 (Jun. 2, 1995).
ZhouNuclear Receptors Have Distinct Affinities for Coativators: Characterization by fluorescence Resonance Energy Transfer,Molecular Endocrinology 12:1594-1604 (1998).
Craddock et al.,Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter,American Physiological Society 274:157-169 (1998).
Blanchard Steven Gerard
Haffner Curt Dale
Kliewer Steven A.
Lehmann Jurgen M.
Maloney Patrick Reed
Anderson Rebecca
Campen Virginia G.
McKane Joseph K.
Smithkline Beecham Corporation
LandOfFree
Use of FXR ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of FXR ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of FXR ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582455